A double‐blinded, randomized, methylprednisolone‐controlled study on the efficacy of oclacitinib in the management of pruritus in cats with nonflea nonfood‐induced hypersensitivity dermatitis

Noli, Chiara; Matricoti, Irina; Schievano, Carlo

doi:10.1111/vde.12720

Cited by 23 publications

(68 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…According to the few published studies, oclacitinib seems to be less effective in cats with signs of allergic disease than in allergic dogs . The high variability in the pharmacokinetic parameters observed in the cat in the present study might explain, at least in part, the lower efficacy of the drug in cats in comparison to dogs.…”

Section: Discussioncontrasting

confidence: 46%

“…According to the few published studies, oclacitinib seems to be less effective in cats with signs of allergic disease than in allergic dogs. 7,10 The high variability in the pharmacokinetic parameters observed in the cat in the present study might explain, at least in part, the lower efficacy of the drug in cats in comparison to dogs. Furthermore, it also is likely that other factors, probably related to disease pathogenesis account for the lower efficacy reported in the feline species.…”

Section: Discussionmentioning

confidence: 79%

“…In fact, this was the frequency of administration of the drug in another study. 10 The optimum dose is more difficult to determine because the therapeutic range of oclacitinib in allergic cats, to the best of the authors' knowledge, has not been established. Nevertheless, considering that the bioavailability is slightly lower in the cat than in dogs and that the clearance in the cat is higher than in the dog (4.45 mL/min/kg versus 4.05 mL/min/kg), it seems appropriate to recommend a higher dose in cats than in dogs.…”

Section: Discussionmentioning

confidence: 99%

“…The high efficacy and the few clinically observed adverse effects of oclacitinib for the treatment of canine allergic dermatitis have led numerous veterinarians to consider the use of this drug in the treatment of allergic dermatitis in cats. Noncontrolled open studies reported promising results and a double‐blinded, randomized, methylprednisolone‐controlled study concluded that oclacitinib appeared to be effective for treating pruritus and lesions in cats with nonflea and or nonfood‐induced hypersensitivity dermatitis . Apart from its off‐label use, one of the main obstacles to prescribing oclacitinib in cats is the lack of pharmacokinetic (PK) data in this species.…”

Section: Introductionmentioning

confidence: 99%

“…Noncontrolled open studies reported promising results [7][8][9] and a double-blinded, randomized, methylprednisolone-controlled study concluded that oclacitinib appeared to be effective for treating pruritus and lesions in cats with nonflea and or nonfood-induced hypersensitivity dermatitis. 10 Apart from its off-label use, one of the main obstacles to prescribing oclacitinib in cats is the lack of pharmacokinetic (PK) data in this species. The pharmacokinetics of oclacitinib in the dog have been well-studied.…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

A pharmacokinetic study of oclacitinib maleate in six cats

Ferrer

Carrasco

Cristòfol

et al. 2019

Veterinary Dermatology

View full text Add to dashboard Cite

Background Oclacitinib is a Janus kinase (JK)1 inhibitor that has been shown to be effective and safe for the treatment of allergic dermatitis in dogs. Its use in cats has been limited by the absence of pharmacokinetic data. Objective To determine the pharmacokinetic parameters of oclacitinib in cats after oral and intravenous administration. Animals Six adult domestic short hair cats. Methods and materials A two period, two treatment design was used in which cats received oclacitinib maleate i.v. and p.o., at a dose of 0.5 mg/kg and 1 mg/kg, respectively. There was a one‐week interval of washout between the two treatments. Cats received each treatment only once. The plasma concentration of oclacitinib was determined by high‐performance liquid chromatography at 0 min, 5 min, 15 min, 30 min, 1 h, 4 h, 6 h, 10 h and 24 h after intravenous.v administration, at 0 min, 15 min, 30 min, 1 h, 2 h, 4 h, 6 h, 10 h and 24 h after p.o. administration. Results After p.o. administration, oclacitinib was absorbed rapidly and almost completely, as shown by an absolute bioavailability of 87% and a Tmax of 35 min. The elimination of the drug also was very rapid as shown by a half‐life of 2.3 h and a clearance calculated as 4.45 mL/min/kg (after i.v. administration). Conclusions and clinical importance The pharmacokinetic parameters of oclacitinib in the cat are similar to those described for the dog, although absorption and elimination are somewhat faster and variability between individuals is somewhat greater. Larger doses and/or shorter dosing intervals would be recommended in cats to achieve similar blood concentrations to those in dogs.

show abstract

Section: Discussioncontrasting

confidence: 46%

Section: Discussionmentioning

confidence: 79%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

A pharmacokinetic study of oclacitinib maleate in six cats

Ferrer

Carrasco

Cristòfol

et al. 2019

Veterinary Dermatology

View full text Add to dashboard Cite

show abstract

Diagnosis and treatment of atopic skin syndrome in cats

Wyatt,

Buckley

2024

In Practice

View full text Add to dashboard Cite

Background: Feline allergic skin disease presents a diagnostic challenge due to the potentially subtle and widely variable clinical presentations known as feline reaction patterns. Cats are often secretive in their pruritic behaviours and so, unlike with canine disease, the clinical history for a cat may not give insight into the presence of pruritus. Once a diagnosis of feline allergic disease is achieved, there are several treatment options available; however, the majority have not been studied extensively in cats and many represent off‐license use.Aim of the article: This article outlines the relevant steps in making a diagnosis of feline atopic skin syndrome and reviews the treatment options available.

show abstract